Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | DRD1 | P21728 | 2/20 | 0.30 |
| ▸ | DRD4 | P21917 | 2/20 | 0.30 |
| ▸ | DRD5 | P21918 | 2/20 | 0.30 |
| ▸ | DRD3 | P35462 | 2/20 | 0.30 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799514 | 1.00 | GAA (0.34) | GAAMGAMSIGMAR1BRD4CA1 | |
| SCHEMBL1183666 | 1.00 | GAA (0.34) | GAAMGAMSIGMAR1BRD4CA1 | |
| SCHEMBL1183788 | 0.82 | SIGMAR1 (0.45) | SIGMAR1BRD4CA1CA2CA4 | |
| SCHEMBL19558041 | 0.79 | SIGMAR1 (0.33) | SIGMAR1BRD4CA1CA2CA4 | |
| SCHEMBL16707760 | 0.79 | NCF1 (0.38) | GAAMGAMPOLBL3MBTL1NCF1 | |
| SCHEMBL22834149 | 0.79 | — | — | |
| SCHEMBL14156572 | 0.79 | SIGMAR1 (0.37) | SIGMAR1BRD4CA1CA2CA4 | |
| SCHEMBL14948558 | 0.78 | KAT6A (0.32) | NCF1 | |
| SCHEMBL90077 | 0.78 | KAT6A (0.32) | NCF1 | |
| SCHEMBL7374703 | 0.78 | SIGMAR1 (0.32) | SIGMAR1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570805-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-119431406-A | Tricyclic compounds and medical uses thereof | 正大天晴药业集团股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024032747-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| WO-2023143352-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海璎黎药业有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | 280 Bio, Inc (US) | 2023-08-03 | — | — | US | disclosed |
| CN-116514848-A | Nitrogen-containing heterocyclic compound, and preparation method and application thereof | 上海璎黎药业有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2023114157-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023072962-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2023-05-04 | — | — | WO | disclosed |
| EP-4169904-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2023-04-26 | — | — | EP | disclosed |
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| EP-2229362-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | AstraZeneca AB (SE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | CCNI, MKI67, TP53 | GAA 354/4885MGAM 3033/4885SIGMAR1 3985/4885 |
| US-20090181967-A1 | New compounds I | GPR119, GLP1R, FABP4 | GAA 1259/4885MGAM 1857/4885SIGMAR1 1324/4885 |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | NRAS, KRAS, RAB8A | GAA 3542/4885MGAM 4668/4885SIGMAR1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.